Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and expand into the U.S.

Alizé Pharma S.A.S. (Lyon, France) had previously employed an asset-centric model whereby it hived off discrete programs into subsidiaries to maximize capital efficiency and the attractiveness of the assets in its pipeline to potential partners (see "Alize's Assets")...